The achievement of this important milestone responds to the Environmental and Social Sustainability Policy of the Group...
3 min
04 Mar, 2022
ROVI reports operating revenue growth of 54% and net profit growth of 151%
2 min
23 Feb, 2022
Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product...
2 min
16 Feb, 2022
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the treatment of...
3 min
15 Feb, 2022
The funding is for the project "Evaluation of chronic toxicity in Risperidone ISM® Quarterly".
1 min
28 Jan, 2022
On the basis of the CHMP’s recommendation, the European Commission will issue its decision on the approval of...
4 min
17 Dec, 2021
ROVI updates its strategy in a meeting with shareholders, investors and analysts
1 min
16 Nov, 2021
ROVI reports operating revenue growth of 53% and doubles its Ebitda
5 min
03 Nov, 2021
ROVI reported the commencement by the Company, effective as of today, 3 November 2021, of a share buyback program
4 min
03 Nov, 2021